You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.
The firm is partnering with the Cleveland Clinic to validate its mutation variant caller platform in hepatocellular cancer cell-free tumor DNA samples.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.
The company has developed a technology for isolating cancer DNA in urine along with specialized PCR assays to identify biomarkers that it believes will offer more accurate and sensitive detection of hepatocellular carcinoma.
The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.
Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.
Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.
In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.